uploads///medical _

What Analysts Are Recommending for CNC and HUM in May

By

May. 29 2019, Updated 1:22 p.m. ET

Share price movements

On May 24, Centene (CNC) closed at $56.87, 2.62% higher than its previous day’s close, 25.15% higher than its 52-week low of $45.44, and 23.65% lower than its 52-week high of $74.49. The company’s market cap was $23.48 billion, and its PE, forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 21.76x, 11.59x, 0.36x, 2.03x, and 3.33x, respectively. The rise in its share price can be attributed to news about certain key activist investors having significant holdings in its stock, including a ~$300 million stake held by Third Point.

Centene’s 14-day RSI (relative strength index) is currently 59.73. The company’s number of outstanding shares is 412.92 million, while its short float ratio is 5.60%.

Article continues below advertisement

On May 24, Humana (HUM) closed at $263.33, 1.48% higher than its previous day’s close, 16.70% higher than its 52-week low of $225.65, and 26.01% lower than its 52-week high of $355.88. The company’s market cap was $35.65 billion, and its PE, forward PE, PS, PB, and PC ratios were 20.23x, 14.03x, 0.61x, 3.29x, and 9.20x, respectively.

Humana’s 14-day RSI is currently 61.91. The company’s number of outstanding shares is 135.38 million, and its short float ratio is 1.66%.

Analysts’ recommendations and target prices

Analysts’ consensus recommendations for both Centene and Humana are “buys.”

Analysts expect an upside of 29.24% for Centene based on the company’s closing price on May 24. Analysts first increased the company’s 12-month consensus target price from $78.53 in February to $79.25 in March but then reduced it to $74.06 in April and $73.50 in May.

Of the 18 analysts covering Centene, eight have given it “strong buys,” eight have given it “buys,” and two have given it “holds.”

Analysts expect an upside of 21.21% for Humana based on the company’s closing price on May 24. Analysts have gradually reduced the company’s 12-month consensus target price from $364.95 in February to $362.70 in March, $351.95 in April, and $319.19 in May.

Of the 23 analysts covering Humana, nine have given it “strong buys,” nine have given it “buys,” and five have given it “holds.”

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.